Adults with hidradenitis suppurativa were at a greater risk for noninfectious uveitis than control individuals, which ...

The following is a summary of “Exploring itch in hidradenitis suppurativa with lessons from atopic dermatitis and psoriasis,” ...

Patients with Hidradenitis Suppurativa (HS) are at a significantly higher risk of obstructive sleep apnea (OSA) compared to ...

MoonLake Immunotherapeutics is set to release results from both the phase 3 VELA-1 and VELA-2 studies in mid-2025. Click here ...

Goldman Sachs analyst Richard Law upgraded MoonLake Immunotherapeutics (MLTX) to Buy from Neutral with a price target of $82, up from $62. The ...

Panelist discusses how delayed medical diagnosis causes significant economic burden through increased treatment costs, prolonged health care interventions, reduced patient productivity, and higher ...

Living with a skin condition like hidradenitis suppurativa (HS) or folliculitis can be challenging, especially when you’re not sure what’s causing your symptoms. Both of these conditions cause ...

Long-term secukinumab treatment among patients with hidradenitis suppurativa did not meet the time to loss of response endpoint at 104 weeks.

UCB, a global biopharmaceutical company, announced today that a single-injection 2 mL prefilled syringe and autoinjector, each containing 320 mg of BIMZELX® (bimekizumab-bkzx) is now available. These ...

HC Wainwright restated their buy rating on shares of InflaRx (NASDAQ:IFRX – Free Report) in a research report released on Thursday morning,Benzinga reports. The brokerage currently has a $8.00 price ...